Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a women's health therapeutics company, today announced that Frank C. Condella, Jr., plans to retire as the Company's President and Chief Executive Officer later this year. A search for his successor is underway and Mr. Condella will continue to serve as President and CEO until his successor is in place.

"Frank Condella has been a strong leader. Bringing the Company through challenging times, he built a terrific team and created a dynamic platform for Juniper's future growth," said Jim Geraghty, Chairman of the Board. "The Board is grateful for his innumerable contributions as CEO, and we are pleased that he will remain involved going forward as a non-executive director."

"Juniper has undergone a dramatic and highly positive transformation over the past several years," said Mr. Condella. "Where the Company was heavily indebted and loss-making when I joined, Juniper now has a growing core business generating cash to advance our exciting pipeline of products for women's health, and is well-positioned to create long-term shareholder value as these programs advance through clinical development and potential commercialization."

Juniper's board of directors has initiated a search for Mr. Condella's successor, and is actively considering candidates for the role.

Under Mr. Condella's leadership, Juniper achieved notable and strategically important milestones which position the Company for long-term value creation, including:

• Acquired and successfully integrated Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development, analytics, and clinical trials manufacturing to clients while concurrently advancing Juniper's proprietary R&D programs;
• Advanced COL-1077 10% lidocaine bioadhesive vaginal gel, an investigational self-administered topical analgesic for gynecologic procedure pain, into clinical development;
• In-licensed a highly-differentiated intravaginal ring (IVR) technology, and advanced three IVR drug candidates into preclinical development;
• Developed the regulatory pathway to file an IND for JNP-0101 oxybutynin ring for overactive bladder in women in late 2016;
• Generated strong revenue growth from CRINONE® and Juniper Pharma Services; and,
• Forged a strong management team and recruited top talent to Juniper's board of directors and Scientific Advisory Board.

Juniper is focused on growing the CRINONE franchise and Juniper Pharma Services while continuing to advance a unique pipeline of vaginally delivered products including our lead clinical candidate, COL-1077. This 10% lidocaine bioadhesive gel is being developed as an acute use anesthetic for minimally invasive gynecologic procedures. Approximately seven million of these are performed annually in the U.S. alone, yet there is no standard of care to manage pain suffered by patients undergoing such procedures.

The Company remains on track to report results of its multi-center double-blind Phase 2b trial evaluating COL-1077 versus placebo bioadhesive vaginal gel in 185 women undergoing pipelle-directed endometrial biopsy with tenaculum placement in the third quarter of 2016.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. The Company is advancing a pipeline of proprietary product candidates that leverage novelintravaginal drug delivery technologies. Juniper's commercial product, CRINONE® 8% (progesterone gel), is marketed by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide and by Allergan, Inc. in the U.S. Please visit www.juniperpharma.com for more information.